Caris Life Sciences Presents Key Biomarker Findings at 2011 ASCO Breast Cancer Symposium

Data Highlights Potential Clinical Utility of Molecular Profiling in Uncovering Therapeutic Options to Treat Breast Cancer

IRVING, TX, September 13, 2011 — Caris Life Sciences™, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, this week at the ASCO Breast Cancer Symposium presented clinical data that demonstrates the importance of understanding individual patients’ unique tumor biology and genetics in personalizing breast cancer treatments. The posters were developed from the analysis of breast cancer patient data from the Caris Target Now™ database of molecular profiles, which includes data on more than 25,000 tumors profiled since 2005 across the spectrum of cancers.

A summary of posters presented follows:

“Frequency Distribution of SPARC in Triple-Negative Breast Cancer Patients,” revealed that SPARC is overexpressed in a significant percentage of triple-negative breast cancer cases, and that molecular profiling for SPARC can identify patients who may benefit from nab-paclitaxel.

“Molecular Profiling of Metastatic Breast Cancer in Body Cavity Fluids,” showed that molecular profiling of malignant effusions can offer insight into the molecular characteristics of malignant cells that are linked to targeted therapies for cancer. This can be particularly useful when other tissue samples, like needle core biopsy or tumor resection, are not available.

“One in eight U.S. women is diagnosed with breast cancer during her lifetime,” said Dr. Raheela Ashfaq, medical director of oncologic pathology at Caris Life Sciences. “Caris Life Sciences believes that the future of cancer treatment lies in accurately evaluating relevant therapeutic targets for an individual patients’ cancer at the molecular level. These studies provide further evidence that breast cancer patients may benefit from a more personalized treatment selection.”

Caris Target Now is an evidence-based molecular profiling service that matches molecular data generated from the individual tumor’s molecular profile with biomarker/drug associations from nearly 100,000 published clinical studies that are reviewed and graded by Caris’ evidence team of PhDs. Caris Target Now then provides a consolidated report outlining personalized treatment options identified in the published literature that indicate which available chemotherapies, biologics, and/or hormone therapies are more likely to elicit a response, as well as those likely to be ineffective.

Further information on SPARC overexpression and molecular profiling, as well as a sample Caris Target Now report can be found at ThinkBiomarkers.com.

About Caris Life Sciences

Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing a series of blood tests utilizing the patented Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.

CONTACT: Caris Life Sciences
Media Inquiries:
Holly Clark
214-596-7060
hclark@carisls.com